PLLA enriched with basement membrane proteins (Matrigel) |
5% PLLA |
6 × 6 × 1 mm |
Solvent-casting particulate leaching |
In vivo
|
Creation of uniform, branched microvascular network |
[91] |
Silk fibroin micronets |
— |
5 × 5 mm |
3D nonwoven substrates made by boiling cocoons and soaking in 98% formic acid |
In vivo
|
Promising vascularization by preculturing with osteoblasts |
[157] |
Gelatin-based sacrificial filament was embedded into a collagen scaffold |
10% gelatin and 3.0 mg/mL collagen |
Channels in the range of 0.7–1.5 mm for the width and 0.5–1.2 mm for the height |
3D bioprinting |
In vitro (human umbilical vein endothelial cells) |
Supporting the viability of tissue up to 5 mm in distance at 5 million cells/mL density under the physiological flow condition |
[1, 158] |
Human outgrowth endothelial cells (OECs) |
Starch-poly(caprolactone) |
— |
As described in [159] |
In vivo
|
Osteoblasts played a pericyte‐like role and supported OEC-derived vessels |
[159] |
Fibroblast growth factor-loaded microspheres |
Alginate scaffold (2% (w/v)) that incorporates tiny poly(lactic-co-glycolic acid) microspheres |
High porosity (90%) with an average pore size of 130 microns |
As described in [160] |
In vitro basic fibroblast growth factor (bFGF) |
The released bFGF induced the formation of large and matured blood vessels |
[161] |
Vascular endothelial growth factor (VEGF), platelet-derived growth factor-BB (PDGF-BB), and transforming growth factor-β1 (TGF-β1) |
Alginate-sulfate/alginate (1% (w/v) solution of sodium alginate and a 0.3% (w/v) solution of hemicalcium gluconate for alginate crosslinking) |
Diameter of 11 mm and thickness of 3 mm |
Freeze-dry technique |
In vivo
|
Creation of mature vessels after 3 months |
[124] |
VEGF and Ang-1 |
Hyaluronan (HA) |
— |
As described in [159] |
In vivo
|
Creation of higher microvessel density after 14 days |
[116] |
FGF-4 plasmid |
Gelatin hydrogel |
— |
Injection of GHG-DNA complex into the hindlimb muscle |
In vivo
|
Promotion of angiogenesis in the newly developed tissues in the GHG-FGF4 group than the naked FGF4-gene four weeks after gene transfer |
[147] |
Plasmid encoding PDGF |
Subcutaneously implanted PLG sponges |
— |
Gas foaming/particulate-leaching process |
In vivo/in vitro
|
Improvement of ECM deposition and capillary formation |
[148] |
Plasmid-mediated VEGF |
PLGA nanoparticles |
— |
Injection of the suspension of VEGF-loaded nanoparticles (VEGF-NPs) into myocardial tissues |
In vivo
|
Higher capillary number compared to the naked plasmid DNA group |
[149] |